CHEK2 and ovarian cancer: The CHEK2 missense mutation (c.470T>C) was previously analyzed in another study of 539 ovarian cystadenomas, 122borderline ovarian tumors, and 447 ovarian cancer cases, including 88 low-grade (G1) tumors [15].